IMMUNOLOGICAL PATHWAYS OF DEVELOPMENT OF EXPERIMENTAL ACQUIRED TOXIC HEMOLYTIC

Main Article Content

Людмила/Ludmila Владимировна/Vladimirovna Сивакова/Sivakova
Елизавета/Elisaveta Андреевна/Andreevna Мамаева/Mamaeva
Полина/Pauline Владимировна/Vladimirovna Косарева/Kosareva
Виталий/Vitalii Петрович/Petrovich Хоринко/Khorinko

Abstract

Toxic hemolytic anemia, induced by drugs and industrial reagents, is provided by combination of different pathogenetic mechanisms. 2-butoxyethanol, a widely used in chemical industry reagent and strong hemolytic poison, was taken for modeling toxic hemolytic anemia. 2-butoxyethanol was injected to white nonlinear rats intraperitoneally. We were taken venous blood for erythrocyte suspension before the experiment. After 10 days we carried out serum agglutination test with autologous erythrocytes. In peripheral blood was found significant decreasing in hemoglobin level and reducing of red blood cells number, increasing in number of reticulocytes. In serum agglutination test was observed the presence of antibodies to own erythrocytes both in group with injection of 2-butoxythanol and in group with injection of 2-butoxyethanol in combination with acute cold stress. It shows the development of autoimmune reaction to own red blood cells. In serum agglutination test with heterologous erythrocytes reaction was positive in control group with average values log - 2,5±1,3. It is explained by genetical identity in outbred population of laboratory rats.

Article Details

How to Cite
Сивакова/Sivakova Л. В., Мамаева/Mamaeva Е. А., Косарева/Kosareva П. В., & Хоринко/Khorinko В. П. (2018). IMMUNOLOGICAL PATHWAYS OF DEVELOPMENT OF EXPERIMENTAL ACQUIRED TOXIC HEMOLYTIC. Bulletin of Perm University. Biology, (3), 287–291. Retrieved from http://press.psu.ru/index.php/bio/article/view/1825
Section
Клиническая лабораторная диагностика
Author Biographies

Людмила/Ludmila Владимировна/Vladimirovna Сивакова/Sivakova, Perm State Medical University

PhD, associate professor of Department of pathophysiology, senior lecturer of Department of microbiology, virology with the course of clinical laboratory diagnostics

Елизавета/Elisaveta Андреевна/Andreevna Мамаева/Mamaeva, Perm State Medical University

Student of medical faculty

Полина/Pauline Владимировна/Vladimirovna Косарева/Kosareva, Perm State Medical University

PhD, MD, chief researcher of Central Research Laboratory, Department of morphological and pathophysiological studies, head of the course of clinical laboratory diagnostics, associate professor of Department of microbiology, virology with the course of clinical laboratory diagnostics

Виталий/Vitalii Петрович/Petrovich Хоринко/Khorinko, Perm State Medical University

PhD, senior researcher of Central Research Laboratory, Department of morphological and pathophysiological studies

References

Baier J. Е., Poehlau D. Is alpha-methyldopa-type autoimmune hemolytic anemia mediated by inter-feron-gamma? // Annals of Hematology. 1994. Nov. Vol. 69(5). P. 249-251.

Baker H.J., Lindsey J.R., Weisbroth S.H. The Laboratory Rat. New York: Academic Press, 1979. Vol. I: Biology and Disease. P. 55-57.

Berger J. Phenylhydrazine haematotoxicity // J. Appl. Biomed. 2007. Vol. 5. P. 125-130.

Betensky M. et al. Immune hemolytic anemia with drug-induced antibodies to carboplatin and vincristine in a pediatric patient with an optic pathway glioma // Transfusion. 2014. Vol. 54 (11) P. 2901-2905.

Bollotte A. et al. Drug-induced hemolytic anemia: A retrospective study of 10 cases // Rev. Med. Interne. 2014. Vol. 35(12). P. 779-789.

El-Ashmawy I.M., Gad S.B., Salama O.M. Grape seed extract prevents azathioprine toxicity in rats // Phytother. Res. 2010. Vol. 24(11). P. 1710-1715.

Exon J.H. et al. Effects of subchronic exposure of rats to 2-methoxyethanol or 2-butoxyethanol: thymic atrophy and immunotoxicity // Fundam. Appl. Toxicol. 1991. May. Vol. 16 (4). P. 830-840.

Garratty G. Drug-induced immune hemolytic anemia // ASH Education Book January. 2009. Vol. 1. P. 73-79.

Garratty G., Arndt P.A. An update on drug-induced immune hemolytic anemia // Immunohematology. 2007. Vol. 23(3). P. 105-119.

Ghanayem B.I., Sanchez I.M., Matthews H.B. Development of tolerance to 2-butoxyethanol-induced hemolytic anemia and studies to elucidate the underlying mechanisms // Toxicol. Appl. Pharmacol. 1992. Feb. Vol. 112 (2). P. 198-206.

Ghanayem B.I., Sullivan C.A. Assessment of the haemolytic activity of 2-butoxyethanol and its major metabolite, butoxyacetic acid, in various mammals including humans // Hum. Exp. Toxicol. 1993. Jul. Vol. 12 (4). P. 305-311.

Haddad H., Mohammad F., Dai Q. Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature // Hematol. Oncol. Stem. Cell Ther. 2014. Dec. Vol. 7(4). P. 162-164.

Haley K.M. et al. Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor // J. Blood Med. 2014. Vol. 15(5). P. 55-58.

Hillman R.S., Ault K.A., Rinder H.M. Hematology in Clinical Practice. 4th Ed. 2005. P. 135-151.

Hematology: basic principles and practice / R. Hoffman et al. 5th ed. 2008. P. 645-659.

Horn S., Bashan N., Gopas J. Phagocytosis of phenyl-hydrazine oxidized and G-6-PD-deficient red blood cells: the role of cell-bound immunoglobulins // Blood. 1991. Oct 1. Vol. 78 (7). P. 1818-1825.

Johnson S.T., Fueger J.T., Gottschall J.L. One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia - a new paradigm // Transfusion. 2007. Vol. 47(4). P. 697-702.

Joybari A.Y. et al. Oxaliplatin-induced renal tubular vacuolization // Ann. Pharmacother. 2014. Vol. 48(6). P. 796-800.

Kannan R., Laboyka R., Low P.S. Isolation and characterization of the hemichrome-stabilized membrane protein aggregates from sickle erythrocytes. Major sites of autologous antibody binding // J. Biol. Chem. 1988. Vol. 263 (27). P. 13766-13773.

Moreira-Rodrigues M. et al. Cardiac dysfunction in HgCl2-induced nephrotic syndrome // Exp. Biol. Med. (Maywood). 2010. Vol. 235 (3). P. 392-400.

Williams Hematology / Kaushansky K. et al. 8th Ed. 2010. P. 777-799.

References

Baier J.E., Poehlau D. Is alpha-methyldopa-type autoimmune hemolytic anemia mediated by inter-feron-gamma? Annals of Hematology. 1994, Nov; 69(5): 249-51.

Baker H.J., Lindsey J.R., Weisbroth S.H. The Laboratory Rat, Volume I: Biology and Disease. New York: Academic Press; 1979: 55-57.

Berger J. Phenylhydrazine haematotoxicity. J Appl Biomed. 2007; 5: 125-30.

Betensky M., Witmer C., Fisher M.J., Nance S., Weiss M.J., Sesok-Pizzini D.A. Immune hemolytic anemia with drug-induced antibodies to carboplatin and vincristine in a pediatric patient with an optic pathway glioma. Transfusion. 2014; 54 (11): 2901-2905.

Bollotte A., Vial T., Bricca P., Bernard C., Broussolle C., Sève P. Drug-induced hemolytic anemia: A retrospective study of 10 cases. Rev Med Interne. 2014; 35(12): 779-89.

El-Ashmawy I.M., Gad S.B., Salama O.M. Grape seed extract prevents azathioprine toxicity in rats. Phytother Res. 2010; 24(11): 1710-1715.

Exon J.H., Mather G.G., Bussiere J.L., Olson D.P., Talcott P.A. Effects of subchronic exposure of rats to 2-methoxyethanol or 2-butoxyethanol: thymic atrophy and immunotoxicity. Fundam Appl Toxicol. 1991 May; 16 (4): 830-40.

Garratty G., Arndt P.A. An update on drug-induced immune hemolytic anemia. Immunohematology. 2007; 23(3): 105-19.

Garratty G. Drug-induced immune hemolytic anemia. ASH Education Book January. 2009; 1: 73-79.

Ghanayem B.I., Sanchez I.M., Matthews H.B. Development of tolerance to 2-butoxyethanol-induced hemolytic anemia and studies to elucidate the underlying mechanisms. Toxicol Appl Pharmacol. 1992 Feb; 112 (2): 198-206.

Ghanayem B.I., Sullivan C.A. Assessment of the haemolytic activity of 2-butoxyethanol and its major metabolite, butoxyacetic acid, in various mammals including humans. Hum Exp Toxicol. 1993 Jul; 12 (4): 305-11.

Haddad H., Mohammad F., Dai Q. Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature. Hematol Oncol Stem Cell Ther. 2014 Dec; 7(4): 162-4.

Haley K.M., Russell Th.B., Boshkov L., Leger R.M., Garratty G., Recht M. et al. Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor. J. Blood Med. 2014; 15(5): 55-8.

Hillman R.S., Ault K.A., Rinder H.M. Hematology in Clinical Practice, 4th Edition. 2005: 135-151.

Hematology: basic principles and practice / R. Hoffman et al. 5th ed. 2008: pp. 645-659.

Horn S., Bashan N., Gopas J. Phagocytosis of phenyl-hydrazine oxidized and G-6-PD-deficient red blood cells: the role of cell-bound immunoglobulins. Blood. 1991 Oct 1; 78 (7): 1818-25.

Johnson S.T., Fueger J.T., Gottschall J.L. One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia - a new paradigm. Transfusion. 2007; 47(4): 697-702.

Joybari A.Y., Sarbaz S., Azadeh P., Mirafsharieh S.A., Rahbari A., Farasatinasab M. et al. Ox-aliplatin-induced renal tubular vacuolization. Ann Pharmacother. 2014; 48(6): 796-800.

Kannan R., Laboyka R., Low P.S. Isolation and characterization of the hemichrome-stabilized membrane protein aggregates from sickle erythrocytes. Major sites of autologous antibody binding. J. Biol. Chem. 1988, 263 (27): 13766-73.

Moreira-Rodrigues M., Henriques-Coelho Т., Moura C., Vasques-Novoa F., Sampaio-Maia В., Pestana M. et al. Cardiac dysfunction in HgCl2-induced nephrotic syndrome. Exp. Biol. Med. (Maywood). 2010; 235 (3): 392-400.

Williams Hematology / Kaushansky K. et al. 8th Edition. 2010: 777-799.